



FIG S1

a HexaBody-CD38 (IgG1-3003-028-E430G)



b daratumumab



c isatuximab





FIG S2



c

70	80	90	100	110	120																																														
HexaBody-CD38	ETVLARCVKYTE	I H P E M R H	VDCQSVWDAFKGAFISKHPCDITEEDYQPLMKGQT	T V P C N																																															
130	140	150	160	170	180																																														
HexaBody-CD38	K I L I W S R I K D L A H Q F T Q V Q	R D M F T L E	D T L L G Y L D	D L T W C G E F	A T S K I N Y Q S C P D W R K D																																														
190	200	210	220	230	240																																														
HexaBody-CD38	SNNPVSVF	W K T V S R R F A E A A	C D V V H V M L D G S R S K I F D K D S T F G S V	E V H N L Q P E K V Q T L E A																																															
250	260	270	280	290																																															
HexaBody-CD38	WVIHGGRED	S	R	D	L	C	Q	D	P	T	I	K	E	L	S	I	I	S	K	R	N	I	Q	F	S	C	K	N	I	Y	R	P	D	K	F	L	Q	C	V	K	N	P	E	D	S	S	C	T	S	E	I

FIG S3







FIG S4**a CD46 expression on tumor cell lines****b CD55 expression on tumor cell lines****c CD59 expression on tumor cell lines**




FIG S5**a CD46****b CD55****c CD59**




FIG S6

FIG S7


a ADCC



b ADCP - loss of Daudi cells



c ADCP - phagocytic activity



d Trogocytosis







FIG S8

FIG S9

a



b



c




FIG S10

